1. Knight RR, Kronenberg D, Zhao M, et al. Human β-cell killing by autoreactive preproinsulin-specific CD8 T-cells is predominantly granule-mediated with the potency dependent upon T-cell receptor avidity. Diabetes. 2013; 62(1): 205-213. doi: 10.2337/db12-0315
2. Luce S, Lemonnier F, Briand J-P, et al. Single insulin-specific CD8+ T-cells show characteristic gene expression profiles in human type 1 diabetes. Diabetes. 2011; 60(12): 3289-3299. doi: 10.2337/db11-0270
3. Skowera A, Ladell K, McLaren JE, et al. β-cell-specific CD8 T-cell phenotype in type 1 diabetes reflects chronic autoantigen exposure. Diabetes. 2014; DB-140332. doi: 10.2337/db14-0332
4. Sachdeva N, Paul M, Badal D, et al. Preproinsulin specific CD8+ T-cells in subjects with latent autoimmune diabetes show lower frequency and different pathophysiological characteristics than those with type 1 diabetes. Clinical Immunology. 2015. doi: 10.1016/j.clim.2015.01.005
5. Sakaguchi S. Naturally arising Foxp3-expressing CD25+ CD4+ regulatory T-cells in immunological tolerance to self and non-self. Nature immunology. 2005; 6(4): 345-352. doi: 10.1038/ni1178
6. Sakaguchi S, Sakaguchi N, Asano M, Itoh M, Toda M. Pillars article: immunologic self-tolerance maintained by activated T-cells expressing IL-2 receptor α-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J. Immunol. 1995.
7. Maloy KJ, Powrie F. Regulatory T-cells in the control of immune pathology. Nature immunology. 2001; 2(9): 816-822. doi: 10.1038/ni0901-816
8. Shevach EM. CD4+ CD25+ suppressor T-cells: more questions than answers. Nature Reviews Immunology. 2002; 2(6): 389-400. doi: 10.1038/nri821
9. Ramsdell F. Foxp3 and natural regulatory T-cells: key to a cell lineage? Immunity. 2003; 19(2): 165-168. doi: 10.1016/s1074-7613(03)00207-3
10. Liu W, Putnam AL, Xu-Yu Z, et al. CD127 expression in- versely correlates with FoxP3 and suppressive function of hu- man CD4+ T reg cells. The Journal of experimental medicine. 2006; 203(7): 1701-1711. doi: 10.1084/jem.20060772
11. Badami E, Sorini C, Coccia M, et al. Defective differentiation of regulatory FoxP3+ T-cells by small-intestinal dendritic cells in patients with type 1 diabetes. Diabetes. 2011; 60(8): 2120- 2124. doi: 10.2337/db10-1201
12. Ferraro A, Socci C, Stabilini A, et al. Expansion of Th17 cells and functional defects in T regulatory cells are key features of the pancreatic lymph nodes in patients with type 1 diabetes. Diabetes. 2011; 60(11): 2903-2913. doi: 10.2337/db11-0090
13. Taams LS, Boot EP, van Eden W, Wauben MH. Anergic T-cells modulate the T-cell activating capacity of antigen- presenting cells. Journal of autoimmunity. 2000; 14(4): 335-341. doi: 10.1006/jaut.2000.0372
14. Eddahri F, Oldenhove G, Denanglaire S, Urbain J, Leo O, Andris F. CD4+ CD25+ regulatory T-cells control the magnitude of T-dependent humoral immune responses to exogenous antigens. European journal of immunology. 2006; 36(4): 855- 863. doi: 10.1002/eji.200535500
15. Mempel TR, Pittet MJ, Khazaie K, et al. Regulatory T-cells reversibly suppress cytotoxic T-cell function independent of effector differentiation. Immunity. 2006; 25(1): 129-141. doi: 10.1016/j.immuni.2006.04.015
16. Bluestone JA, Tang Q. How do CD4+ CD25+ regulatory T-cells control autoimmunity? Current opinion in immunology. 2005; 17(6): 638-642. doi: 10.1016/j.coi.2005.09.002
17.TangQ,BluestoneJA.TheFoxp3+regulatoryT-cell:ajack of all trades, master of regulation. Nature immunology. 2008; 9(3): 239-244. doi: 10.1038/ni1572
18. Roncarolo MG, Bacchetta R, Bordignon C, Narula S, Levings MK. Type 1 T regulatory cells. Immunological reviews. 2001; 182(1): 68-79. doi: 10.1034/j.1600-065X.2001.1820105.x
19. Pot C, Apetoh L, Kuchroo VK, editors. Type 1 regulatory T-cells (Tr1) in autoimmunity. Seminars in immunology. Elsevier, 2011. doi: 10.1016/j.smim.2011.07.005
20. Okamura T, Fujio K, Sumitomo S, Yamamoto K. Roles of LAG3 and EGR2 in regulatory T-cells. Annals of the rheumatic diseases. 2012; 71(Suppl 2): i96-i100. doi: 10.1136/annrheumdis-2011-200588
21. Yadav M, Louvet C, Davini D, et al. Neuropilin-1 distinguishes natural and inducible regulatory T-cells among regulatory T-cell subsets in vivo. The Journal of experimental medicine. 2012; 209(10): 1713-1722. doi: 10.1084/jem.20120822
22. de Lafaille MAC, Lafaille JJ. Natural and adaptive foxp3+ regulatory T-cells: more of the same or a division of labor? Immunity. 2009; 30(5): 626-635. doi: 10.1016/j. immuni.2009.05.002
23. Lu L, Ma J, Li Z, et al. All-trans retinoic acid promotes TGF- β-induced Tregs via histone modification but not DNA demethy- lation on Foxp3 gene locus. PloS one. 2011; 6(9): e24590. doi: 10.1371/journal.pone.0024590
24. Tai X, Cowan M, Feigenbaum L, Singer A. CD28 costimulation of developing thymocytes induces Foxp3 expression and regulatory T-cell differentiation independently of interleukin 2. Nature immunology. 2005; 6(2): 152-162. doi: 10.1038/ni1160
25. Benson MJ, Pino-Lagos K, Rosemblatt M, Noelle RJ. All- trans retinoic acid mediates enhanced T reg cell growth, differ- entiation, and gut homing in the face of high levels of co-stim- ulation. The Journal of experimental medicine. 2007; 204(8): 1765-1774. doi: 10.1084/jem.20070719
26. Shevach EM, Tran DQ, Davidson TS, Andersson J. The critical contribution of TGF-β to the induction of Foxp3 expression and regulatory T-cell function. European journal of immunology. 2008; 38(4): 915-917. doi: 10.1002/eji.200738111
27. Bilate AM, Lafaille JJ. Induced CD4+ Foxp3+ regulatory T-cells in immune tolerance. Annual review of immunology. 2012; 30: 733-758. doi: 10.1146/annurev-immunol-020711-075043
28. Salomon B, Lenschow DJ, Rhee L, et al. B7/CD28 costimulation is essential for the homeostasis of the CD4+ CD25+ immunoregulatory T-cells that control autoimmune diabetes. Immunity. 2000; 12(4): 431-440. doi: 10.1016/s1074-7613(00)80195-8
29. Cheng G, Yu A, Dee MJ, Malek TR. IL-2R signaling is essential for functional maturation of regulatory T-cells during thymic development. The Journal of Immunology. 2013; 190(4): 1567-1575. doi: 10.4049/jimmunol.1201218
30. Stritesky GL, Jameson SC, Hogquist KA. Selection of self- reactive T-cells in the thymus. Annual review of immunology. 2012; 30: 95. doi: 10.1146/annurev-immunol-020711-075035
31. Hsieh C-S, Lee H-M, Lio C-WJ. Selection of regulatory T-cells in the thymus. Nature Reviews Immunology. 2012; 12(3): 157-167. doi: 10.1038/nri3155
32. Josefowicz SZ, Lu L-F, Rudensky AY. Regulatory T-cells: mechanisms of differentiation and function. Annual review of immunology. 2012; 30: 531-564. doi: 10.1146/annurev. immunol.25.022106.141623
33. Lee H-M, Bautista JL, Scott-Browne J, Mohan JF, Hsieh C-S. A broad range of self-reactivity drives thymic regulatory T-cell selection to limit responses to self. Immunity. 2012; 37(3): 475-486. doi: 10.1016/j.immuni.2012.07.009
34. Round JL, Mazmanian SK. Inducible Foxp3+ regulatory T-cell development by a commensal bacterium of the intestinal microbiota. Proceedings of the National Academy of Sciences. 2010; 107(27): 12204-12209. doi: 10.1073/pnas.0909122107
35. Lathrop SK, Bloom SM, Rao SM, et al. Peripheral education of the immune system by colonic commensal microbiota. Na- ture. 2011; 478(7368): 250-254. doi: 10.1038/nature10434
36. Lin X, Chen M, Liu Y, et al. Advances in distinguishing natural from induced Foxp3+ regulatory T-cells. International journal of clinical and experimental pathology. 2013; 6(2): 116.
37. Bruder D, Probst-Kepper M, Westendorf AM, et al. Frontline: Neuropilin-1: a surface marker of regulatory T-cells. European journal of immunology. 2004; 34(3): 623-630. doi: 10.1002/ eji.200324799
38. Thornton AM, Korty PE, Tran DQ, et al. Expression of He- lios, an Ikaros transcription factor family member, differentiates thymic-derived from peripherally induced Foxp3+ T regulatory cells. The Journal of Immunology. 2010; 184(7): 3433-3441. doi: 10.4049/jimmunol.0904028
39. Kim YC, Bhairavabhotla R, Yoon J, et al. Oligodeoxynucle- otides stabilize Helios-expressing Foxp3+ human T regulatory cells during in vitro expansion. Blood. 2012; 119(12): 2810- 2818. doi: 10.1182/blood-2011-09-377895
40. Lal G, Bromberg JS. Epigenetic mechanisms of regulation of Foxp3 expression. Blood. 2009; 114(18): 3727-3735. doi: 10.1182/blood-2009-05-219584
41. McClymont SA, Putnam AL, Lee MR, et al. Plasticity of human regulatory T-cells in healthy subjects and patients with type 1 diabetes. The Journal of Immunology. 2011; 186(7): 3918-3926. doi: 10.4049/jimmunol.1003099
42. Kukreja A, Cost G, Marker J, et al. Multiple immuno-regula- tory defects in type-1 diabetes. The Journal of clinical investiga- tion. 2002; 109(109 (1)): 131-140. doi: 10.1172/JCI13605
43. Ryba M, Rybarczyk-Kapturska K, Zorena K, Myśliwiec M, Myśliwska J. Lower Frequency of CD62L high and Higher Fre- quency of TNFR2. Mediators of inflammation. 2011; 2011. doi: 10.1155/2011/645643
44. Ryba-Stanisławowska M, Skrzypkowska M, Myśliwska J, Myśliwiec M. The serum IL-6 profile and Treg/Th17 peripheral cell populations in patients with type 1 diabetes. Mediators of inflammation. 2013; 2013. doi: 10.1155/2013/205284
45. Ryba-Stanisławowska M, Rybarczyk-Kapturska K, Myśliwiec M, Myśliwska J. Elevated Levels of Serum IL-12 and IL-18 are Associated with Lower Frequencies of CD4+ CD25highFOXP3+ Regulatory T-cells in Young Patients with Type 1 Diabetes. Inflammation. 2014; 37(5): 1513-1520. doi: 10.1007/s10753-014-9878-1
46. Brusko T, Wasserfall C, McGrail K, et al. No alterations in the frequency of FOXP3+ regulatory T-cells in type 1 diabetes. Diabetes. 2007; 56(3): 604-612. doi: 10.2337/db06-1248
47. Xufré C, Costa M, Roura-Mir C, et al. Low frequency of GITR+ T-cells in ex vivo and in vitro expanded Treg cells from type 1 diabetic patients. International immunology. 2013: dxt020. doi: 10.1093/intimm/dxt020
48. Zóka A, Barna G, Somogyi A, et al. Extension of the CD4+ Foxp3+ CD25-/low regulatory T-cell subpopulation in type 1 diabetes mellitus. Autoimmunity. 2014; 1-9. doi: 10.3109/08916934.2014.992518
49. Willcox A, Richardson S, Bone A, Foulis A, Morgan N. Analysis of islet inflammation in human type 1 diabetes. Clini- cal & Experimental Immunology. 2009; 155(2): 173-181. doi: 10.1111/j.1365-2249.2008.03860.x
50. Lindley S, Dayan CM, Bishop A, Roep BO, Peakman M, Tree TI. Defective suppressor function in CD4+ CD25+ T-cells from patients with type 1 diabetes. Diabetes. 2005; 54(1): 92-99. doi: 10.2337/diabetes.54.1.92
51. Brusko TM, Wasserfall CH, Clare-Salzler MJ, Schatz DA, Atkinson MA. Functional defects and the influence of age on the frequency of CD4+ CD25+ T-cells in type 1 diabetes. Diabetes. 2005; 54(5): 1407-1414. doi: 10.2337/diabetes.54.5.1407
52. Haseda F, Imagawa A, Murase-Mishiba Y, Terasaki J, Hanafusa T. CD4+ CD45RA− FoxP3high activated regulatory T-cells are functionally impaired and related to residual insulin- secreting capacity in patients with type 1 diabetes. Clinical & Experimental Immunology. 2013; 173(2): 207-216. doi: 10.1111/cei.12116
53. Long SA, Cerosaletti K, Bollyky PL, et al. Defects in IL- 2R signaling contribute to diminished maintenance of FOXP3 expression in CD4+ CD25+ regulatory T-cells of type 1 diabetic subjects. Diabetes. 2010; 59(2): 407-415. doi: 10.2337/db09- 0694
54. Zhou X, Bailey-Bucktrout SL, Jeker LT, et al. Instability of the transcription factor Foxp3 leads to the generation of pathogenic memory T-cells in vivo. Nature immunology. 2009; 10(9): 1000-1007. doi: 10.1038/ni.1774
55. Schneider A, Rieck M, Sanda S, Pihoker C, Greenbaum C, Buckner JH. The effector T-cells of diabetic subjects are resistant to regulation via CD4+ FOXP3+ regulatory T-cells. The Journal of Immunology. 2008; 181(10): 7350-7355. doi: 10.4049/jimmunol.181.10.7350
56. Lawson J, Tremble J, Dayan C, et al. Increased resistance to CD4+ CD25hi regulatory T-cell-mediated suppression in patients with type 1 diabetes. Clinical & Experimental Immunology. 2008; 154(3): 353-359. doi: 10.1111/j.1365-2249.2008.03810.x
57. Zhang J, Gao W, Yang X, et al. Tolerogenic vaccination reduced effector memory CD4 T-cells and induced effector memory Treg cells for type I diabetes treatment. PloS one. 2013; 8(7): e70056. doi: 10.1371/journal.pone.0070056
58. Johnson MC, Garland AL, Nicolson SC, et al. β-Cell–Specific IL-2 Therapy Increases Islet Foxp3+ Treg and Suppresses Type 1 Diabetes in NOD Mice. Diabetes. 2013; 62(11): 3775-3784. doi: 10.2337/db13-0669
59. Bilbao D, Luciani L, Johannesson B, Piszczek A, Rosenthal N. Insulin-like growth factor-1 stimulates regulatory T-cells and suppresses autoimmune disease. EMBO molecular medicine. 2014; e201303376. doi: 10.15252/emmm.201303376
60. Tian J, Dang H, Nguyen AV, Chen Z, Kaufman DL. Combined therapy with GABA and proinsulin/alum acts synergistically to restore long-term normoglycemia by modulating T-Cell autoimmunity and promoting β-Cell replication in newly diabetic NOD mice. Diabetes. 2014; 63(9): 3128-3134. doi: 10.2337/db13-1385
61. Turner MS, Isse K, Fischer DK, Turnquist HR, Morel PA. Low TCR signal strength induces combined expansion of Th2 and regulatory T-cell populations that protect mice from the development of type 1 diabetes. Diabetologia. 2014; 57(7): 1428-1436. doi: 10.1007/s00125-014-3233-9
62. Lin G-J, Sytwu H-K, Yu J-C, et al. Dimethyl sulfoxide inhibits spontaneous diabetes and autoimmune recurrence in non-obese diabetic mice by inducing differentiation of regulatory T-cells. Toxicology and applied pharmacology. 2015; 282(2): 207-214. doi: 10.1016/j.taap.2014.11.012
63. Marek-Trzonkowska N, Myśliwiec M, Dobyszuk A, et al. Therapy of type 1 diabetes with CD4+ CD25 high CD127- regulatory T-cells prolongs survival of pancreatic islets-Results of one year follow-up. Clinical Immunology. 2014; 153(1): 23- 30. doi: 10.1016/j.clim.2014.03.016
64. Bluestone JA. Regulatory T-cell therapy: is it ready for the clinic? Nature Reviews Immunology. 2005; 5(4): 343-349. doi: 10.1038/nri1574
65. Hill JA, Hall JA, Sun C-M, et al. Retinoic acid enhances Foxp3 induction indirectly by relieving inhibition from CD4+ CD44 hi cells. Immunity. 2008; 29(5): 758-770. doi: 10.1016/j. immuni.2008.09.018
66. Rossetti M, Spreafico R, Saidin S, et al. Ex vivo-expanded but not in vitro-induced human regulatory T-cells are candidates for cell therapy in autoimmune diseases thanks to stable demethylation of the FOXP3 regulatory T-cell-specific demethylated region. The Journal of Immunology. 2015; 194(1): 113-124. doi: 10.4049/jimmunol.1401145
67. Fantini M, Becker C, Monteleone G, Pallone F, Galle P, Neurath M. TGF-beta induces a regulatory phenotype in CD4+ CD25-T-cells through FoxP3 induction and dowuregulation of Smad7. Gastroenterology. Wb Saunders Co Independence Square West Curtis Center, Ste 300, Philadelphia, PA 19106- 3399 USA, 2004 .
68. Josefowicz SZ, Rudensky A. Control of regulatory T-cell lineage commitment and maintenance. Immunity. 2009; 30(5): 616-625. doi: 10.1016/j.immuni.2009.04.009
69. Lu Y, Gu J, Lu H, et al. iTreg induced from CD39+ naive T-cells demonstrate enhanced proliferate and suppressive ability. International immunopharmacology. 2015. doi: 10.1016/j. intimp.2015.03.039
70. Chai J-G, Coe D, Chen D, Simpson E, Dyson J, Scott D. In vitro expansion improves in vivo regulation by CD4+ CD25+ regulatory T-cells. The Journal of Immunology. 2008; 180(2): 858-869. doi: 10.4049/jimmunol.180.2.858
71. Groux H, O’Garra A, Bigler M, et al. A CD4+ T-cell subset inhibits antigen-specific T-cell responses and prevents colitis. Nature. 1997; 389(6652): 737-742. doi: 10.1038/39614
72. Jonuleit H, Schmitt E, Schuler G, Knop J, Enk AH. Induction of interleukin 10–producing, nonproliferating CD4+ T-cells with regulatory properties by repetitive stimulation with allogeneic immature human dendritic cells. The Journal of experimental medicine. 2000; 192(9): 1213-1222. doi: 10.1084/jem.192.9.1213
73. Gad M, Kristensen NN, Kury E, Claesson MH. Characteriza- tion of T-regulatory cells, induced by immature dendritic cells, which inhibit enteroantigen-reactive colitis-inducing T-cell re- sponses in vitro and in vivo. Immunology. 2004; 113(4): 499- 508. doi: 10.1111/j.1365-2567.2004.01977.x
74. Rao PE, Petrone AL, Ponath PD. Differentiation and expansion of T-cells with regulatory function from human peripheral lymphocytes by stimulation in the presence of TGF-β. The Journal of Immunology. 2005; 174(3): 1446-1455. doi: 10.4049/jimmunol.174.3.1446
75. Walker MR, Carson BD, Nepom GT, Ziegler SF, Buckner JH. De novo generation of antigen-specific CD4+ CD25+ regulatory T-cells from human CD4+ CD25–cells. Proceedings of the National Academy of Sciences of the United States of America. 2005; 102(11): 4103-4108. doi: 10.1073/pnas.0407691102
76. DiPaolo RJ, Brinster C, Davidson TS, Andersson J, Glass D, Shevach EM. Autoantigen-specific TGFβ-induced Foxp3+ regulatory T-cells prevent autoimmunity by inhibiting dendritic cells from activating autoreactive T-cells. The Journal of Immunology. 2007; 179(7): 4685-4693. doi: 10.4049/jimmunol.179.7.4685
77. Zhao C, Shi G, Vistica BP, et al. Induced regulatory T-cells (iTregs) generated by activation with anti-CD3/CD28 antibodies differ from those generated by the physiological-like activation with antigen/APC. Cellular immunology. 2014; 290(2): 179- 184. doi: 10.1016/j.cellimm.2014.06.004
78. Kang H-K, Liu M, Datta SK. Low-dose peptide tolerance therapy of lupus generates plasmacytoid dendritic cells that cause expansion of autoantigen-specific regulatory T-cells and contraction of inflammatory Th17 cells. The Journal of Immunology. 2007; 178(12): 7849-7858. doi: 10.4049/jimmunol.178.12.7849
79. Hamdi H, Godot V, Maillot M-C, et al. Induction of antigen- specific regulatory T lymphocytes by human dendritic cells ex- pressing the glucocorticoid-induced leucine zipper. Blood. 2007; 110(1): 211-219. doi: 10.1182/blood-2006-10-052506
80. Tarbell KV, Petit L, Zuo X, et al. Dendritic cell–expanded, islet-specific CD4+ CD25+ CD62L+ regulatory T-cells restore normoglycemia in diabetic NOD mice. The Journal of experimental medicine. 2007; 204(1): 191-201. doi: 10.1084/jem.20061631
81. Pillai V, Ortega SB, Wang C, Karandikar NJ. Transient regulatory T-cells: a state attained by all activated human T- cells. Clinical immunology. 2007; 123(1): 18-29. doi: 10.1016/j. clim.2006.10.014
82. Prevosto C, Zancolli M, Canevali P, Zocchi MR, Poggi A. Generation of CD4+ or CD8+ regulatory T-cells upon mesenchymal stem cell-lymphocyte interaction. Haematologica. 2007; 92(7): 881-888. doi: 10.3324/haematol.11240
83. Francisco LM, Salinas VH, Brown KE, et al. PD-L1 regulates the development, maintenance, and function of induced regulatory T-cells. The Journal of experimental medicine. 2009; 206(13): 3015-3029. doi: 10.1084/jem.20090847
84. Long SA, Walker MR, Rieck M, et al. Functional islet-specific Treg can be generated from CD4+ CD25- T-cells of healthy and type 1 diabetic subjects. European journal of immunology. 2009; 39(2): 612-620. doi: 10.1002/eji.200838819
85. Brusko TM, Koya RC, Zhu S, et al. Human antigen-specific regulatory T-cells generated by T-cell receptor gene transfer. PloS one. 2010; 5(7): e11726. doi: 10.1371/journal.pone.0011726
86. Zheng J, Liu Y, Lau Y-L, Tu W. CD40-activated B cells are more potent than immature dendritic cells to induce and expand CD4+ regulatory T-cells. Cellular & molecular immunology. 2010; 7(1): 44-50. doi: 10.1038/cmi.2009.103
87.MotaC,Nunes-SilvaV,PiresAR,etal.Delta-like1-mediated notch signaling enhances the in vitro conversion of human memory CD4 T-cells into FOXP3-expressing regulatory T-cells. The Journal of Immunology. 2014; 193(12): 5854-5862. doi: 10.4049/jimmunol.1400198
88. Romani R, Pirisinu I, Calvitti M, et al. Stem cells from hu- man amniotic fluid exert immunoregulatory function via se- creted indoleamine 2, 3-dioxygenase1. Journal of cellular and molecular medicine. 2015. doi: 10.1111/jcmm.12534
89. Akbarpour M, Goudy KS, Cantore A, et al. Insulin B chain 9-23 gene transfer to hepatocytes protects from type 1 diabetes by inducing Ag-specific FoxP3+ Tregs. Science Translational Medicine. 2015; 7(289): 289ra81-289ra81. doi: 10.1126/sci-translmed.aaa3032
90. Chatenoud L, Bluestone JA. CD3-specific antibodies: a por- tal to the treatment of autoimmunity. Nature Reviews Immunol- ogy. 2007; 7(8): 622-632. doi: 10.1038/nri2134
91. Orban T, Farkas K, Jalahej H, et al. Autoantigen-specific regulatory T-cells induced in patients with type 1 diabetes mellitus by insulin B-chain immunotherapy. Journal of autoimmunity. 2010; 34(4): 408-415. doi: 10.1016/j.jaut.2009.10.005
92. Bock G, Prietl B, Mader JK, et al. The effect of vitamin D supplementation on peripheral regulatory T-cells and β cell function in healthy humans: a randomized controlled trial. Diabetes/metabolism research and reviews. 2011; 27(8): 942- 945. doi: 10.1002/dmrr.1276
93. Hjorth M, Axelsson S, Rydén A, Faresjö M, Ludvigsson J, Casas R. GAD-alum treatment induces GAD 65-specific CD4+ CD25 high FOXP3+ cells in type 1 diabetic patients. Clinical immunology. 2011; 138(1): 117-126. doi: 10.1016/j.clim.2010.10.004
94. Marek-Trzonkowska N, Myśliwiec M, Dobyszuk A, et al. Administration of CD4+ CD25 high CD127-regulatory T-cells preserves β-Cell function in Type 1 Diabetes in children. Diabetes care. 2012; 35(9): 1817-1820. doi: 10.2337/dc12-0038
95. Long SA, Rieck M, Sanda S, et al. Rapamycin/IL-2 combination therapy in patients with type 1 diabetes augments Tregs yet transiently impairs β-cell function. Diabetes. 2012; 61(9): 2340-2348. doi: 10.2337/db12-0049
96. Haller MJ, Gitelman SE, Gottlieb PA, et al. Anti-thymocyte globulin/G-CSF treatment preserves β cell function in patients with established type 1 diabetes. The Journal of clinical investi- gation. 2014; 125(125(1)). doi: 10.1172%2FJCI78492
97. Bonifacio E, Ziegler A-G, Klingensmith G, et al. Effects of high-dose oral insulin on immune responses in children at high risk for type 1 diabetes: the Pre-POINT randomized clinical trial. JAMA. 2015; 313(15): 1541-1549. doi: 10.1001/jama.2015.2928
98. Penaranda C, Bluestone JA. Is antigen specificity of autoreactive T-cells the key to islet entry? Immunity. 2009; 31(4): 534-536. doi: 10.1016/j.immuni.2009.09.006
99. Lennon GP, Bettini M, Burton AR, et al. T-cell islet accumulation in type 1 diabetes is a tightly regulated, cell- autonomous event. Immunity. 2009; 31(4): 643-653. doi: 10.1016/j.immuni.2009.07.008
100. Tang Q, Henriksen KJ, Bi M, et al. In vitro-expanded antigen-specific regulatory T-cells suppress autoimmune diabetes. The Journal of experimental medicine. 2004; 199(11): 1455-1465. doi: 10.1084/jem.20040139
101. Bluestone JA, Tang Q. Therapeutic vaccination using CD4+ CD25+ antigen-specific regulatory T-cells. Proceedings of the National Academy of Sciences. 2004; 101(Suppl 2): 14622- 14626. doi: 10.1073/pnas.0405234101
102. Larkin J, Picca CC, Caton AJ. Activation of CD4+ CD25+ regulatory T-cell suppressor function by analogs of the selecting peptide. European journal of immunology. 2007; 37(1): 139- 146. doi: 10.1002/eji.200636577
103. Kasagi S, Zhang P, Che L, et al. In vivo–generated antigen-specific regulatory T-cells treat autoimmunity without compromising antibacterial immune response. Science translational medicine. 2014; 6(241): 241ra78-241ra78. doi: 10.1126/scitranslmed.3008895
104. Coombes JL, Siddiqui KR, Arancibia-Cárcamo CV, et al. A functionally specialized population of mucosal CD103+ DCs induces Foxp3+ regulatory T-cells via a TGF-β–and retinoic acid–dependent mechanism. The Journal of experimental medicine. 2007; 204(8): 1757-1764. doi: 10.1084/jem.20070590
105. Ito T, Yang M, Wang Y-H, et al. Plasmacytoid dendritic cells prime IL-10–producing T regulatory cells by inducible co- stimulator ligand. The Journal of experimental medicine. 2007; 204(1): 105-115. doi: 10.1084/jem.20061660
106. Yamazaki S, Dudziak D, Heidkamp GF, et al. CD8+ CD205+ splenic dendritic cells are specialized to induce Foxp3+ regulatory T-cells. The Journal of Immunology. 2008; 181(10): 6923-6933. doi: 10.4049/jimmunol.181.10.6923
107. Tu W, Lau Y-L, Zheng J, et al. Efficient generation of human alloantigen-specific CD4+ regulatory T-cells from naive precursors by CD40-activated B cells. Blood. 2008; 112(6): 2554-2562. doi: 10.1182/blood-2008-04-152041
108. Noyan F, Lee YS, Zimmermann K, et al. Isolation of human antigen-specific regulatory T-cells with high suppressive function. European journal of immunology. 2014; 44(9): 2592- 2602. doi: 10.1002/eji.201344381
109. Yang XO, Nurieva R, Martinez GJ, et al. Molecular antagonism and plasticity of regulatory and inflammatory T-cell programs. Immunity. 2008; 29(1): 44-56. doi: 10.1016/j.immuni.2008.05.007
110. Komatsu N, Mariotti-Ferrandiz ME, Wang Y, Malissen B, Waldmann H, Hori S. Heterogeneity of natural Foxp3+ T-cells: a committed regulatory T-cell lineage and an uncommitted minor population retaining plasticity. Proceedings of the National Academy of Sciences. 2009; 106(6): 1903-1908. doi: 10.1073/pnas.0811556106
111. Oldenhove G, Bouladoux N, Wohlfert EA, et al. Decrease of Foxp3+ Treg cell number and acquisition of effector cell phenotype during lethal infection. Immunity. 2009; 31(5): 772-786. doi: 10.1016/j.immuni.2009.10.001
112. Miyao T, Floess S, Setoguchi R, et al. Plasticity of Foxp3+ T-cells reflects promiscuous Foxp3 expression in conventional T-cells but not reprogramming of regulatory T-cells. Immunity. 2012; 36(2): 262-275. doi: 10.1016/j.immuni.2011.12.012
113. Yurchenko E, Shio MT, Huang TC, et al. Inflammation- driven reprogramming of CD4+ Foxp3+ regulatory T-cells into pathogenic Th1/Th17 T effectors is abrogated by mTOR inhibition in vivo. PloS one. 2012; 7(4): e35572. doi: 10.1371/journal.pone.0035572
114. Pasare C, Medzhitov R. Toll pathway-dependent blockade of CD4+ CD25+ T-cell-mediated suppression by dendritic cells. Science. 2003; 299(5609): 1033-1036. doi: 10.1126/science.1078231
115. Valencia X, Stephens G, Goldbach-Mansky R, Wilson M, Shevach EM, Lipsky PE. TNF downmodulates the function of human CD4+ CD25hi T-regulatory cells. Blood. 2006; 108(1): 253-261. doi: 10.1182/blood-2005-11-4567
116. Peluso I, Fantini MC, Fina D, et al. IL-21 counteracts the regulatory T-cell-mediated suppression of human CD4+ T lymphocytes. The Journal of Immunology. 2007; 178(2): 732- 739. doi: 10.4049/jimmunol.178.2.732
117. Ruprecht CR, Gattorno M, Ferlito F, et al. Coexpression of CD25 and CD27 identifies FoxP3+ regulatory T-cells in inflamed synovia. The Journal of experimental medicine. 2005; 201(11): 1793-1803. doi: 10.1084/jem.20050085
118. Komatsu N, Okamoto K, Sawa S, et al. Pathogenic conversion of Foxp3+ T-cells into TH17 cells in autoimmune arthritis. Nature medicine. 2014; 20(1): 62-68. doi: 10.1038/nm.3432
119. Vaarala O, Atkinson MA, Neu J. The Perfect storm for type 1 diabetes the complex interplay between intestinal micro- biota, gut permeability, and mucosal immunity. Diabetes. 2008; 57(10): 2555-2562. doi: 10.2337/db08-0331
120. Kukreja A, Maclaren NK. NKT-cells and type-1 diabetes and the” hygiene hypothesis” to explain the rising incidence rates. Diabetes technology & therapeutics. 2002; 4(3): 323-333. doi: 10.1089/152091502760098465
121. Sun C-M, Hall JA, Blank RB, et al. Small intestine lamina propria dendritic cells promote de novo generation of Foxp3 T reg cells via retinoic acid. The Journal of experimental medicine. 2007; 204(8): 1775-1785. doi: 10.1084/jem.20070602
122. Coombes JL, Powrie F. Dendritic cells in intestinal immune regulation. Nature Reviews Immunology. 2008; 8(6): 435-446. doi: 10.1038/nri2335
123. Jaakkola I, Jalkanen S, Hänninen A. Diabetogenic T-cells are primed both in pancreatic and gut-associated lymph nodes in NOD mice. European journal of immunology. 2003; 33(12): 3255-3264. doi: 10.1002/eji.200324405
124. Hänninen A, Nurmela R, Maksimow M, Heino J, Jalkanen S, Kurts C. Islet β-cell-specific T-cells can use different homing mechanisms to infiltrate and destroy pancreatic islets. The American journal of pathology. 2007; 170(1): 240-250. doi: 10.2353/ajpath.2007.060142
125. Geuking MB, Cahenzli J, Lawson MA, et al. Intestinal bacterial colonization induces mutualistic regulatory T-cell responses. Immunity. 2011; 34(5): 794-806. doi: 10.1016/j.immuni.2011.03.021
126. Atarashi K, Tanoue T, Oshima K, et al. Treg induction by a rationally selected mixture of Clostridia strains from the human microbiota. Nature. 2013; 500(7461): 232-236. doi: 10.1038/ nature12331
127. Zuo L, Yuan K-T, Yu L, Meng Q-H, Chung PC-K, Yang D-H. Bifidobacterium infantis attenuates colitis by regulating T-cell subset responses. World journal of gastroenterology: WJG. 2014; 20(48): 18316. doi: 10.3748/wjg.v20.i48.18316
128. Calcinaro F, Dionisi S, Marinaro M, et al. Oral probiotic administration induces interleukin-10 production and prevents spontaneous autoimmune diabetes in the non-obese diabetic mouse. Diabetologia. 2005; 48(8): 1565-1575. doi: 10.1007/s00125-005-1831-2
129. Robert S, Gysemans C, Takiishi T, et al. Oral delivery of Glutamic Acid Decarboxylase (GAD)-65 and IL10 by Lactococ- cus lactis reverses diabetes in recent-onset NOD mice. Diabetes. 2014; 63(8): 2876-287. doi: 10.2337/db13-1236
130. Smith PM, Howitt MR, Panikov N, et al. The microbial metabolites, short-chain fatty acids, regulate colonic Treg cell homeostasis. Science. 2013; 341(6145): 569-573. doi: 10.1126/science.1241165
131. Furusawa Y, Obata Y, Fukuda S, et al. Commensal microbe- derived butyrate induces the differentiation of colonic regulatory T-cells. Nature. 2013; 504(7480): 446-450. doi: 10.1038/nature12721
132. Ferrante RJ, Kubilus JK, Lee J, et al. Histone deacetylase inhibition by sodium butyrate chemotherapy ameliorates the neurodegenerative phenotype in Huntington’s disease mice. The Journal of neuroscience. 2003; 23(28): 9418-9427. doi: 10.1523/jneurosci.23-28-09418.2003
133. Tao R, de Zoeten EF, Özkaynak E, et al. Deacetylase inhibition promotes the generation and function of regulatory T-cells. Nature medicine. 2007; 13(11): 1299-1307. doi: 10.1038/nm1652
134. De Zoeten EF, Wang L, Sai H, Dillmann WH, Hancock WW. Inhibition of HDAC9 increases T regulatory cell function and prevents colitis in mice. Gastroenterology. 2010; 138(2): 583-594. doi: 10.1053/j.gastro.2009.10.037
135. Manicassamy S, Reizis B, Ravindran R, et al. Activation of β-catenin in dendritic cells regulates immunity versus toler- ance in the intestine. Science. 2010; 329(5993): 849-853. doi: 10.1126/science.1188510
136. Ganapathy V, Thangaraju M, Prasad PD, Martin PM, Singh N. Transporters and receptors for short-chain fatty acids as the molecular link between colonic bacteria and the host. Current opinion in pharmacology. 2013; 13(6): 869-874. doi: 10.1016/j.coph.2013.08.006
137. Blad CC, Tang C, Offermanns S. G protein-coupled recep- tors for energy metabolites as new therapeutic targets. Nature Reviews Drug Discovery. 2012; 11(8): 603-619. doi: 10.1038/nrd3777
138. Singh N, Gurav A, Sivaprakasam S, et al. Activation of Gpr109a, receptor for niacin and the commensal metabolite butyrate, suppresses colonic inflammation and carcinogenesis. Immunity. 2014; 40(1): 128-139. doi: 10.1016/j.immuni.2013.12.007
139. Kang SW, Kim SH, Lee N, et al. 1, 25-Dihyroxyvitamin D3 promotes FOXP3 expression via binding to vitamin D response elements in its conserved noncoding sequence region. The Jour- nal of Immunology. 2012; 188(11): 5276-5282. doi: 10.4049/jimmunol.1101211
140. Takiishi T, Ding L, Baeke F, et al. Dietary supplementation with high doses of regular vitamin D3 safely reduces diabetes in- cidence in nod mice when given early and long-term. Diabetes. 2014; DB-131559. doi: 10.2337/db13-1559
141. Kunisawa J, Hashimoto E, Ishikawa I, Kiyono H. A pivotal role of vitamin B9 in the maintenance of regulatory T-cells in vitro and in vivo. PloS one. 2012; 7(2): e32094. doi: 10.1371/journal.pone.0032094
142. Kim SV, Xiang WV, Kwak C, et al. GPR15-mediated homing controls immune homeostasis in the large intestine mucosa. Science. 2013; 340(6139): 1456-1459. doi: 10.1126/sci- ence.1237013